Denosumab in the Treatment of Postmenopausal Women with Osteoporosis: Fracture Outcomes, BMD, and Morphological Assessment
Publisher
Springer Singapore
Reference33 articles.
1. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG RANK RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401–19.
2. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry, and strength. Curr Opin Pharmacol. 2005;5:618–25.
3. Elliott R, Kostenuik P, Chen C, et al. Denosumab is a selective inhibitor of human receptor activator of NF-κB ligand that blocks osteoclast formation in vitro and in vivo. Eur J Ca Suppl. 2006;4:62.
4. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.
5. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libinati C, Kanis J. Denosumab reduces the risk of osteoporotic fracutres in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012;27(7):1480–6.